Skip to main content
. Author manuscript; available in PMC: 2013 Oct 23.
Published in final edited form as: Gene Ther. 2012 Apr 5;20(3):255–261. doi: 10.1038/gt.2012.31

Figure 2.

Figure 2

CPA suppresses the primary immune response to MV. (a) Measles-susceptible CD46 transgenic mice were given saline i.p., or 4 i.p. doses of CPA at 2.5 or 3 mg per dose or 8 oral doses of CPA at 1 mg per dose as shown in the schematic diagram. MV-NIS was given i.p. to groups 2 to 5 at 1 day post saline or CPA. (b) Anti-MV antibody (Ab) titers were measured 1 month later and the fold change in anti-MV Ab titers compared with saline control group 1 was plotted (n = 8 per group, mean ± s.e.m.). The respective fold increase in anti-MV Ab titer in groups 3, 4 and 5 were significantly (P<0.005, t-test) less than group 2.